<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02576431</url>
  </required_header>
  <id_info>
    <org_study_id>LOXO-TRK-15002</org_study_id>
    <nct_id>NCT02576431</nct_id>
  </id_info>
  <brief_title>Study of LOXO-101 (Larotrectinib) in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)</brief_title>
  <official_title>A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 (Larotrectinib) in Subjects With NTRK Fusion-Positive Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loxo Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loxo Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II, multi-center, open-label study of patients with advanced solid tumors harboring a
      fusion of NTRK1, NTRK2 or NTRK3.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II, multi-center, open-label study of patients with advanced solid tumors
      harboring a fusion of NTRK1, NTRK2 or NTRK3. Patients with NTRK1, NTRK2 or NTRK3
      fusion-positive cancers will be identified through molecular assay.

      LOXO-101 will be administered orally at 100mg twice daily (BID), with each cycle consisting
      of 28 days of dosing administered on a continuous basis.

      The study will analyze 8 cohorts of patients with tumors bearing NTRK fusions, including non
      small cell lung cancer, thyroid cancer, sarcoma, colorectal cancer, salivary gland cancer,
      biliary cancer and primary CNS tumor, as well as a cohort that will enroll patients not
      included in the histologies listed above.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate of confirmed CR or PR as determined by an Independent Radiology Committee using RECIST 1.1 or RANO criteria</measure>
    <time_frame>Up to 30 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate of confirmed CR or PR as determined by the treating investigator using RECIST 1.1 or RANO criteria</measure>
    <time_frame>Up to 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response for subjects with best overall response of confirmed CR or PR by Independent Radiology Committee</measure>
    <time_frame>Up to 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response for subjects with best overall response of confirmed CR or PR by the treating investigator</measure>
    <time_frame>Up to 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>Number of moths from initiation of Loxo-101 to the earlier of diease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Through study completion up to 42 months</time_frame>
    <description>Number of months from the initiation of LOXO-101 to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Progression Free Survival following initiation of Loxo-101 to that following the line of therapy immediately preceding Loxo-101</measure>
    <time_frame>UP to 30 months</time_frame>
    <description>In each subject who has received prior therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Up to 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Adverse Events</measure>
    <time_frame>Up to 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Adverse Events</measure>
    <time_frame>Up to 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in clinical safety laboratory values</measure>
    <time_frame>Up to 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in vital signs</measure>
    <time_frame>Up to 30 months</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">151</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Thyroid Neoplasms</condition>
  <condition>Sarcoma</condition>
  <condition>Colorectal Neoplasms</condition>
  <condition>Salivary Gland Neoplasms</condition>
  <condition>Biliary Tract Neoplasms</condition>
  <condition>Brain Neoplasm, Primary</condition>
  <condition>Carcinoma, Ductal, Breast</condition>
  <condition>Melanoma</condition>
  <condition>Solid Tumors</condition>
  <condition>Glioblastoma</condition>
  <condition>Bile Duct Neoplasms</condition>
  <condition>Astrocytoma</condition>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Pontine Glioma</condition>
  <condition>Pancreatic Neoplasms</condition>
  <condition>Ovarian Neoplasms</condition>
  <condition>Carcinoma, Renal Cell</condition>
  <condition>Cholangiocarcinoma</condition>
  <condition>Carcinoma</condition>
  <condition>Carcinoma, Bronchogenic</condition>
  <condition>Bronchial Neoplasms</condition>
  <condition>Lung Neoplasms</condition>
  <condition>Respiratory Tract Neoplasms</condition>
  <condition>Thoracic Neoplasms</condition>
  <condition>Neoplasms, Nerve Tissue</condition>
  <condition>Nevi and Melanomas</condition>
  <arm_group>
    <arm_group_label>Non Small Cell Lung Cancer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Adult Solid Tumors Measurable Disease by RECIST 1.1 Oral LOXO-101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thyroid</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Adult Solid Tumors Measurable Disease by RECIST 1.1 Oral LOXO-101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarcoma</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Adult Solid Tumors Measurable Disease by RECIST 1.1 Oral LOXO-101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colorectal</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Adult Solid Tumors Measurable Disease by RECIST 1.1 Oral LOXO-101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salivary</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Adult Solid Tumors Measurable Disease by RECIST 1.1 Oral LOXO-101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biliary</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Adult Solid Tumors Measurable Disease by RECIST 1.1 Oral LOXO-101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary CNS</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Brain Tumor Measurable by RANO Oral LOXO-101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>All Other Solid Tumors</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Tumor Histology not in Cohorts 1-7 Evaluable but not Measurable Disease Oral LOXO-101</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LOXO-101</intervention_name>
    <description>Oral capsule of LOXO-101 - 100mg BID</description>
    <arm_group_label>Non Small Cell Lung Cancer</arm_group_label>
    <arm_group_label>Thyroid</arm_group_label>
    <arm_group_label>Sarcoma</arm_group_label>
    <arm_group_label>Colorectal</arm_group_label>
    <arm_group_label>Salivary</arm_group_label>
    <arm_group_label>Biliary</arm_group_label>
    <arm_group_label>Primary CNS</arm_group_label>
    <arm_group_label>All Other Solid Tumors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Locally-advanced or metastatic malignancy with an NTRK1, NTRK2 or NTRK3 gene fusion,
             identified through molecular assays as routinely performed at CLIA or other
             similarly-certified laboratories.

          2. Subjects must have received prior standard therapy appropriate for their tumor type
             and stage of disease, or in the opinion of the Investigator, would be unlikely to
             tolerate or derive clinical benefit from appropriate standard of care therapy.

          3. Adequate organ function as defined by the following criteria:

               -  Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) &lt; 2.5
                  upper limit of normal (ULN), or AST and ALT &lt; 5 ULN if liver function
                  abnormalities are due to underlying malignancy.

               -  Total bilirubin &lt; 2.5 ULN. Subjects with a known history of Gilberts Disease and
                  an isolated elevation of indirect bilirubin are eligible.

               -  Serum creatinine &lt; 2.0 ULN OR an estimated glomerular filtration rate ≥ 30
                  mL/minute using the Cockroft-Gault formula.

        Key Exclusion Criteria:

        1. Pregnancy or lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nora Ku, MD</last_name>
    <role>Study Director</role>
    <affiliation>Loxo Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patient Advocacy</last_name>
    <phone>1-855-NTRK-123</phone>
    <email>clinicaltrials@loxooncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California - Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Rosen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shivaani Kummar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medstar Hospital Washington</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dennis Priebat, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Raez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jyoti Patel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Farago, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Demetri, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Chamberlin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Gutierrez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Grand'Maison, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Drilon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina (UNC)</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juneko Grilley-Olson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Grant, MD, JD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Davendra Sohal, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashwin Sama, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wafik El-Deiry, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Avera Cancer Institute</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Leyland-Jones, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Berlin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Hong, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inova Health System</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Deeken, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington - Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Baik, MD, MPH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Ma, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Copenhagen University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrik Lassen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Italiano</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ray McDermott, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Do-Youn Oh</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keunchil Park, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun Cheol Chung, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Português de Oncologia do Porto Francisco Gentil</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuno Sousa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre</name>
      <address>
        <city>Outram</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Tan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cinta Hierro Carbó</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Moreno, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncologico Clara Campal</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentina Boni</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS Trust Royal London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Propper</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Forster</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton (UHS)</name>
      <address>
        <city>Southampton</city>
        <zip>S016 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Crabb</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Ireland</country>
    <country>Korea, Republic of</country>
    <country>Portugal</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2015</study_first_submitted>
  <study_first_submitted_qc>October 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2015</study_first_posted>
  <last_update_submitted>September 5, 2017</last_update_submitted>
  <last_update_submitted_qc>September 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NTRK Fusion Positive</keyword>
  <keyword>LOXO-101</keyword>
  <keyword>Loxo</keyword>
  <keyword>TRK</keyword>
  <keyword>TRK Fusion</keyword>
  <keyword>NTRK1</keyword>
  <keyword>NTRK2</keyword>
  <keyword>NTRK3</keyword>
  <keyword>TRKA</keyword>
  <keyword>TRKB</keyword>
  <keyword>TRKC</keyword>
  <keyword>ETV6</keyword>
  <keyword>NTRK</keyword>
  <keyword>larotrectinib</keyword>
  <keyword>fusion</keyword>
  <keyword>tumors</keyword>
  <keyword>CNS tumors</keyword>
  <keyword>solid tumors</keyword>
  <keyword>central nervous system tumors</keyword>
  <keyword>solid CNS tumors</keyword>
  <keyword>primary CNS tumor</keyword>
  <keyword>Advanced CNS tumor</keyword>
  <keyword>Metastatic CNS tumor</keyword>
  <keyword>NTRK1 fusion</keyword>
  <keyword>NTRK2 fusion</keyword>
  <keyword>NTRK3 fusion</keyword>
  <keyword>ETV6-NTRK3</keyword>
  <keyword>ETV6 fusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
    <mesh_term>Thoracic Neoplasms</mesh_term>
    <mesh_term>Respiratory Tract Neoplasms</mesh_term>
    <mesh_term>Bronchial Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Bronchogenic</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Bile Duct Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ductal, Breast</mesh_term>
    <mesh_term>Neoplasms, Nerve Tissue</mesh_term>
    <mesh_term>Salivary Gland Neoplasms</mesh_term>
    <mesh_term>Nevi and Melanomas</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

